CTSB (cathepsin B)

2008-04-01   Zala Jevnikar , Janko Kos 

Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia





The gene for human cathepsin B is located on chromosome 8p22 and it comprises 12 exons. The transcript length is 1017 bps which are translated to 339 residues preproenzyme. Cathepsin B mRNA consists of several variants produced by alternative exon splicing. Most variations involve the 5- and 3-UTR. Cathepsin B mRNAs lacking exon 2 are predominant in human tumours. In addition, human breast and colon carcinomas and human melanoma contain a cathepsin B transcript that is also missing exon 3 encoding the signal peptide and 7 residues of the activation propeptide.


Transcription is initiated from more than one promoter region. In addition to the promoter region upstream from exon 1, there could be promoters upstream from exons 3 and 4. Each promoter region could be regulated independently.


Atlas Image
Richardson diagram of procathepsin B structure: a-helixes are shown in red and β-sheets in green. Catalytic residues are shown in ball-and-stick representation: Cys108 in yellow, His278 in purple and Asn298 in pink. His189 on the occluding loop is shown in purple in ball-and-stick representation. The propeptide is shown in grey (MEROPS: the peptidase database - C01.060).


Cathepsin B belongs to the superfamily of papain-like cysteine proteases. It is synthesized as a preproenzyme of 339 amino acid residues with a calculated Mr of 37 822 Da. The presence of a signal sequence and N-glycosylation sites shows that cathepsin B is targeted to the endosomal/lysosomal compartment via the mannose-6-phosphate receptor pathway.
Under certain pathological conditions, cathepsin B is translocated to the peripheral cytoplasmic and plasma membrane region or secreted from cells. Processing to the mature enzyme form occurs in the acidic environment of the trans-Golgi and the lysosome. Procathepsin B can be activated by cathepsin D, elastase and cathepsins G, uPA/PLAU or tPA./PLAT Activation occurs by cleaving and dissociation of 62 residue proregion. The final proteolytic event is the cleavage between residues 47 and 50 to yield a two-chain form of the enzyme with the excision of a dipeptide. Access of substrate into the active site of cathepsin B is controlled by an 18-residue-long insertion (Pro 107 Asp 124), termed the occluding loop which provides two His residues to bind the carboxylic group of the C-terminus of the substrate. This explains the preferred carboxypeptidase activity of the enzyme.
However, cathepsin B can also act as an endopeptidase since the occluding loop is flexible and can move from the active site cleft when endopeptidase substrate binds to the enzyme. For colorimetric and fluorimetric assay of cathepsin B peptidyl-NHPhNO2 and  NHMec substrates are most commonly used. When the selectivity for cathepsin B over other lysosomal cysteine peptidases such as cathepsin H, cathepsin L and cathepsin S is required, Z-Arg-Arg+ NHPhNO2 or Z-Arg-Arg+NHMec should be used.
Cathepsin B is inhibited by a2-macroglobulin, the cystatin family of inhibitors of papain-like cysteine peptidases and by the equistatin family. The displacement of the occluding loop is required for the binding of cystatin C to the active-site cleft. Most of the natural cysteine protease inhibitors are therefore much less effective against cathepsin B than other members of the papain family. Cathepsin B is susceptible to the various classes of irreversible inhibitors that have been developed for the papain family. Selectivity has been achieved through the synthesis of E-64 derivatives CA-074, CA-030 and isobutyl-epoxysuccinyl-Leu-Pro.


Based on the structure of the mouse and human promoter regions, cathepsin B is classified as a housekeeping gene. Although this implies that the expression of the gene is constitutive, increases in the amounts of mRNA for cathepsin B have been reported in many human tumours. At the gene level, the altered expression results from gene amplification, elevated transcription, use of alternative promoters and alternative splicing. These molecular changes lead to increased cathepsin B protein levels and in turn redistribution, secretion and increased activity. Over-expression of cathepsin B has been reported in several human tumours including tumours of brain, colon, prostate and thyroid.


Cathepsin B asts as a lysosomal cysteine protease in normal cells and tissues. In malignant tumours and premalignant lesions, the expression of cathepsin B is highly up-regulated and the enzyme is secreted and becomes associated with the cell surface. Secretion of procathepsin B occurs principally as a result of increased expression, whereas secretion of active cathepsin B seems to be facilitated by lysosomal exocytosis or extracellular processing by surface activators. Cathepsin B is localized to caveolae on the tumour surface, where binding to the annexin II heterotetramer occurs. Activation of cathepsin B on the cell surface leads to the regulation of downstream proteolytic cascade(s). A truncated form of cathepsin B lacking the signal peptide and part of the propeptide, and encoded by the construct missing exons 2 and 3, was neither found in the Golgi apparatus nor in lysosomal vesicles, but rather in the cytoplasm as patches associated with membranous and short fibrillar elements.


In the lysosomes, cathepsin B is involved in the turnover of proteins and plays various roles in maintaining the normal metabolism of cells. Cathepsin B protein and activity levels have been found to be higher in many human tumours including tumours of breast, cervix and ovary, colon, stomach, glioma, lung and thyroid. The redistribution of cathepsin B to the cell surface in cancer cells occurs coincidently with degradation of the underlying extracellular matrix (ECM). Cathepsin B can affect ECM directly causing its proteolytic degradation or indirectly via activation or amplification of other ECM-degrading proteases. The endopeptidase activity of cathepsin B should be important in direct extra- or intra-cellular remodelling of ECM, since it is capable of degrading ECM proteins laminin, fibronectin, and collagen IV, facilitating tumour cell invasion and metastasis. Digestion of fibronectin results in exposure of the CS-1 sequence, which is recognized by the integrin receptor a4β1, linking cathepsin B to cellular signal transduction events. Cathepsin B indirectly enhances proteolysis by activating the urokinase-type pro-plasminogen which can subsequently activate the plasmin-metalloproteinases proteolytic pathway.
Moreover, cathepsin B may change the balance between metalloproteinases (MMP) and their inhibitors and directly activates some of the MMPs - interstitial procollagenase (proMMPs-3) and prostromelysin-1 (proMMPs-2), and cleaves and inactivates some of the MMP inhibitors TIMP-1 and TIMP-2. In such a way, cathepsin B assists tumour cells in their detachment from ECMs and metastasis. Moreover, during proteolytic breakdown of ECMs, some ECM-bound growth factors such as bFGF, EGF, TGF-β, IGF-I and VEGF may be liberated and become bioavailable for growth modulation of receptor-partner expressing tumour and stroma cells.


Cathepsin B is encoded by a single gene in humans and other mammals and it exhibit a high degree of sequence homology to other cysteine proteinases of the papain superfamily. In contrast, cathepsin B-like cysteine protease genes occur as large multigene families in a wide range of parasitic helminths and free-living nematodes. Several cathepsin B-like genes were shown to be expressed in the intestine of the parasitic worm Haemonchus contortus or in the free-living nematode Caenorhabditis elegans. No function for any of the cathepsin B-like cysteine protease, has been resolved but it is believed that they are involved in induction of protective immunity.



not yet reported for Homo sapiens.


not yet reported for Homo sapiens.

Implicated in

Entity name
Invasive cancers
Over-expression of cathepsin B mRNA has been reported in several human tumours including tumours of brain, colon, prostate and thyroid. However, increased expression of cathepsin B, in premalignant lesions, suggests that this enzyme may play a role in the transformation of pre-malignant lesions to malignant tumours. Moreover, it has been found that cathepsin B expression often increases specifically at the invasive edge of tumour cells. Although, a few studies indicate a correlation between cathepsin B mRNA over-expression and tumour invasion, numerous studies have been focused on cathepsin B expression at the level of protein and activity. Cathepsin B protein and activity levels have been found to be higher in many human tumours including tumours of breast, cervix and ovary, colon, stomach, bladder, glioma, lung, prostate and thyroid.
Cathepsin B was shown to participate in processes of tumour growth, vascularisation, invasion and metastasis. Its level in tumour tissue extracts can provide useful clinical information to predict disease-free and overall survival in breast, prostate, lung, colorectal and other cancer patients. Cathepsin B expression correlated with the invasiveness, especially in malignant breast and prostate tumours. In melanoma and colorectal cancer patients high serum levels of cathepsins B correlated with shorter survival. It was found that both cysteine cathepsins and their endogenous protein inhibitors stefins and cystatin C can also predict prognosis when measured extracellularly. However, the cathepsin B/cystatin C complex was found to be less abundant in sera of patients with malignant tumours than in those with benign diseases or in healthy controls, suggesting an imbalance between the enzyme and its inhibitor in cancer patients.
Cathepsin B can degrade components of the extracellular matrix (laminin, fibronectin and collagen IV) and intact basement membrane in vitro. In vivo studies have found that there is an inverse correlation between cathepsin B staining and basement membrane (type IV collagen or laminin) staining in bladder, gastric, lung and colon carcinomas. This would be consistent with a functional role for cathepsin B in degrading these extracellular matrix components in vivo.
Once activated, cathepsin B may activate pro-uPA, which then in turn can convert plasminogen to plasmin. Plasmin is capable of degrading several components of the extracellular matrix may activate MMPs such as interstitial collagenase (MMP-1), stromelysin-1 (MMP-3), gelatinase B (MMP-9), metalloelastase (MMP-12), and collagenase-3 (MMP-13). These MMPs can degrade many different components of the extracellular matrix and can activate other MMPs. Cathepsin B, in addition to indirectly activating MMPs via the plaminogen activator/plasmin cascade, may also directly activate MMPs, e.g., interstitial collagenase and stromelysin-1. In vitro assays, however, do not replicate the complex tumour environment and thus we are not sure if these interactions between proteases actually occur in vivo.
Entity name
Neurodegenerative diseases
The regulated secretory pathway of neurons is the major source of toxic beta-amyloid peptides that accumulates in Alzheimers disease. Extracellular beta-amyloid peptides secreted from that pathway is generated by beta-secretase processing of amyloid precursor protein. Previously, cysteine protease activity was demonstrated as the major beta-secretase activity in regulated secretory vesicles of neuronal chromaffin cells. The representative cysteine protease activity in these secretory vesicles was identified as cathepsin B. These results demonstrate a newly identified role for cathepsin B in neurosecretory vesicles in the production of biologically active peptides. Inhibitors of cathepsin B may be considered as therapeutic agents to reduce toxic beta-amyloid peptides in Alzheimers disease.
Entity name
Cardiovascular diseases
Cathepsin cysteine proteases have been shown to play a role in several cardiovascular diseases, including restenosis and neointima formation, aneurysm formation, and atherosclerosis. Cathepsin B is mainly expressed in macrophages, but also in smooth muscle cells and human umbilical venous endothelial cells. Its mRNA and protein levels were found to be increased in atherosclerotic lesions of apoE-deficient mice, and cathepsin B immunoreactivity was highest in areas next to the lumen and in macrophages. Relocation of cathepsin B from the lysosome into the cytosol, where it may act as cleavage enzymes in apoptosis, may eventually contribute to the formation of the necrotic core and can be considered an atherosclerosis-stimulating role. On the other hand, inhibition of cathepsin B reduced lysosomal degradation of modified LDL, thereby inducing foam cell formation, which can be regarded as an atherosclerosis-protective role for cathepsin B.


Pubmed IDLast YearTitleAuthors
70440051981E-64 [L-trans-epoxysuccinyl-leucyl-amido(4-guanidino)butane] and related epoxides as inhibitors of cysteine proteinases.Barrett AJ et al
76220421995Identification of two new exons and multiple transcription start points in the 5'-untranslated region of the human cathepsin-B-encoding gene.Berquin IM et al
15774561992Confirmation of the human cathepsin B gene (CTSB) assignment to chromosome 8.Fong D et al
84946081993Characterization of the cathepsin B gene and multiple mRNAs in human tissues: evidence for alternative splicing of cathepsin B pre-mRNA.Gong Q et al
92197251997Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines.Heidtmann HH et al
170811162006Unique neuronal functions of cathepsin L and cathepsin B in secretory vesicles: biosynthesis of peptides in neurotransmission and neurodegenerative disease.Hook VY et al
158783372005Carboxypeptidases cathepsins X and B display distinct protein profile in human cells and tissues.Kos J et al
91532501997Equistatin, a new inhibitor of cysteine proteinases from Actinia equina, is structurally related to thyroglobulin type-1 domain.Lenarcic B et al
120882022002Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients.Levicar N et al
175223802007Cathepsin cysteine proteases in cardiovascular disease.Lutgens SP et al
126107282003The alternative use of exons 2 and 3 in cathepsin B mRNA controls enzyme trafficking and triggers nuclear fragmentation in human cells.Müntener K et al
111505002000Cystatin inhibition of cathepsin B requires dislocation of the proteinase occluding loop. Demonstration By release of loop anchoring through mutation of his110.Pavlova A et al
145872992003Cathepsin B and its role(s) in cancer progression.Podgorski I et al
125817402003Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro.Premzl A et al
110328342001Cathepsin B-like cysteine proteases confer intestinal cysteine protease activity in Haemonchus contortus.Shompole S et al
157619612005Proteolytic-antiproteolytic balance and its regulation in carcinogenesis.Skrzydlewska E et al
86173551996Crystal structures of human procathepsin B at 3.2 and 3.3 Angstroms resolution reveal an interaction motif between a papain-like cysteine protease and its propeptide.Turk D et al
128870512003Molecular regulation of human cathepsin B: implication in pathologies.Yan S et al

Other Information

Locus ID:

NCBI: 1508
MIM: 116810
HGNC: 2527
Ensembl: ENSG00000164733


dbSNP: 1508
ClinVar: 1508
TCGA: ENSG00000164733


Gene IDTranscript IDUniprot

Expression (GTEx)



PathwaySourceExternal ID
Autophagy - animalKEGGko04140
Antigen processing and presentationKEGGko04612
Autophagy - animalKEGGhsa04140
Antigen processing and presentationKEGGhsa04612
NOD-like receptor signaling pathwayKEGGko04621
NOD-like receptor signaling pathwayKEGGhsa04621
Renin secretionKEGGhsa04924
Renin secretionKEGGko04924
Immune SystemREACTOMER-HSA-168256
Adaptive Immune SystemREACTOMER-HSA-1280218
MHC class II antigen presentationREACTOMER-HSA-2132295
Innate Immune SystemREACTOMER-HSA-168249
Toll-Like Receptors CascadesREACTOMER-HSA-168898
Trafficking and processing of endosomal TLRREACTOMER-HSA-1679131
Extracellular matrix organizationREACTOMER-HSA-1474244
Collagen formationREACTOMER-HSA-1474290
Assembly of collagen fibrils and other multimeric structuresREACTOMER-HSA-2022090
Degradation of the extracellular matrixREACTOMER-HSA-1474228
Collagen degradationREACTOMER-HSA-1442490
Neutrophil degranulationREACTOMER-HSA-6798695

Protein levels (Protein atlas)

Not detected


Pubmed IDYearTitleCitations
158317162005Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection.435
194148002009Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASC-containing inflammasome.113
215082632011Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway.104
151223322004Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis.91
200082852010Listeria monocytogenes-infected human peripheral blood mononuclear cells produce IL-1beta, depending on listeriolysin O and NLRP3.86
199131212009Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.85
152746322004Purification and characterization of the human gamma-secretase complex.83
273454232016Running-Induced Systemic Cathepsin B Secretion Is Associated with Memory Function.69
222661112012Cathepsin B inhibition limits bone metastasis in breast cancer.59
224644432012ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression.51


Zala Jevnikar ; Janko Kos

CTSB (cathepsin B)

Atlas Genet Cytogenet Oncol Haematol. 2008-04-01

Online version: http://atlasgeneticsoncology.org/gene/40202/ctsb-(cathepsin-b)